RxDoctor Payments Data

Michael Franklin, MD

Neurology · Saint Petersburg, FLNPI 1548277189

Payments from drug & device makers

$20,002in general payments, 2019–2025

Across 470 payments — averaging $42.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Novartis$687
  • Pfizer$566
  • GE HealthCare$515
  • AstraZeneca$444
  • UCB, Inc.$419
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$9,82449%
  • Travel & lodging$6493%
  • Food & beverage$9,51248%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)100$12,360
Novartis38$687
Pfizer38$566
GE HealthCare19$515
AstraZeneca(2 entities)16$444
UCB, Inc.17$419
Biogen20$392
Takeda Pharmaceuticals U.S.A., Inc.12$360
Lilly USA, LLC17$328
Lundbeck LLC10$298
Teva Pharmaceuticals USA, Inc.26$270
Genentech USA, Inc.13$268
Argenx US, Inc.7$267
Amgen9$231
Neurocrine Biosciences, Inc.10$202
Sanofi9$179
Catalyst Pharmaceuticals, Inc.5$136
Bristol Myers Squibb6$112
Sunovion Pharmaceuticals Inc.7$109
Eisai Inc.5$107
Acadia Pharmaceuticals Inc5$105
Tanabe Pharma America, Inc.4$104
SK Life Science, Inc.3$99
CSL Behring4$93
Hemosonics LLC1$91
Supernus Pharmaceuticals, Inc.7$89
Sumitomo Pharma America, Inc.5$83
Vanda Pharmaceuticals Inc.4$82
Axsome Therapeutics, Inc.3$65
EMD Serono, Inc.4$64
Jazz Pharmaceuticals Inc.3$60
TG Therapeutics, Inc.2$55
Upsher-smith Laboratories LLC3$54
Zyla Life Sciences, Inc.3$53
Acorda Therapeutics, Inc2$49
Banner Life Sciences, LLC2$48
Alnylam Pharmaceuticals Inc.2$43
Aucta Pharmaceuticals, Inc.4$36
Sarepta Therapeutics, Inc.1$29
Nevro Corp.2$29
Johnson & Johnson1$28
Portola Pharmaceuticals, LLC2$28
Biohaven Pharmaceutical Holding Company Ltd.1$27
Avanir Pharmaceuticals, Inc.2$26
Averitas Pharma Inc.1$26
Xeris Pharmaceuticals, Inc.1$25
Bausch Health US, LLC1$24
Grifols USA, LLC1$24
Impel Pharmaceuticals LLC1$24
Merz Pharmaceuticals, LLC1$23
Microtransponder, Inc.1$22
Vertical Pharmaceuticals, LLC1$21
Tonix Medicines, Inc.1$21
Amneal Pharmaceuticals LLC1$18
Cycle Pharmaceuticals Inc1$18
Biohaven Pharmaceuticals, Inc.1$17
Idorsia Pharmaceuticals US Inc1$16
PTC Therapeutics, Inc.1$13
Collegium Pharmaceutical, Inc.1$13
Medtronic1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,002 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$166,248
Medicare patients
200
Services billed
7,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4675$427,668
AubagioTeriflunomide30$283,597
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$258,154
CopaxoneGlatiramer Acetate26$150,697
TysabriNatalizumab13$109,857
TecfideraDimethyl Fumarate12$105,960
QuliptaAtogepant71$77,808
Nurtec OdtRimegepant Sulfate60$59,158
UbrelvyUbrogepant54$56,783
Teriflunomide15$51,207
Emgality PenGalcanezumab-Gnlm53$46,319
Aimovig AutoinjectorErenumab-Aooe44$40,102
ZavzpretZavegepant Hcl27$28,804
NuedextaDextromethorphan Hbr/Quinidine13$26,242
BotoxOnabotulinumtoxina17$26,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$24$427,66875 claims
SanofiAubagio$179$283,59730 claims
CSL BehringPrivigen$93$258,15411 claims
BiogenTysabri, Tecfidera$392$215,81725 claims
AbbVieQulipta, Ubrelvy, Botox$12,360$160,757142 claims
Teva Pharmaceuticals USA, Inc.Copaxone$270$150,69726 claims
PfizerNurtec Odt, Zavzpret, Eliquis, Lyrica$566$105,249118 claims
Avanir Pharmaceuticals, Inc.Nuedexta$26$26,24213 claims
Collegium Pharmaceutical, Inc.Xtampza Er$13$14,49320 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$18$5,09948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →